UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Epidemiological Proileof Children with Malnutrition at Child Malnutrition Treatment Center (CMTC)in Saurashtra Region

Healthline (Gujarat India), 2023-12, Vol.14 (4), p.325-331

2023

Volltextzugriff (PDF)

Epidemiological Profile of Children with Malnutrition at Child Malnutrition Treatment Center (CMTC) in Saurashtra Region

Healthline (Gujarat India), 2023-12, Vol.14 (4), p.325-331

2023

Volltextzugriff (PDF)

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

American journal of hematology, 2023-03, Vol.98 (3), p.449-463

2023

Volltextzugriff (PDF)

Intensive Care in India in 2018-2019: The Second Indian Intensive Care Case Mix and Practice Patterns Study

Indian journal of critical care medicine, 2021-10, Vol.25 (10), p.1093-1107

2021

Volltextzugriff (PDF)

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT133-CT133

2020

Volltextzugriff (PDF)

Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, October 2019

MMWR. Morbidity and mortality weekly report, 2019-11, Vol.68 (43), p.985-989

2019

Volltextzugriff (PDF)

Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.874-874

2018

Volltextzugriff (PDF)

Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.880-880

2018

Volltextzugriff (PDF)

Traumatic Lingual Hematoma Resulting in Bilateral Temporal Mandibular Joint Dislocations

The Journal of emergency medicine, 2018-05, Vol.54 (5), p.e101-e103

2018

Volltextzugriff (PDF)

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin

Breast cancer research and treatment, 2016-02, Vol.155 (3), p.431-440

2016

Volltextzugriff (PDF)

Effective treatment of HER2-amplified breast cancer by targeting HER3 and [beta]1 integrin

Breast cancer research and treatment, 2016-02, Vol.155 (3), p.431

2016

Volltextzugriff (PDF)

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib

Oncotarget, 2015-12, Vol.6 (38), p.41123-41133

2015

Volltextzugriff (PDF)

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers

Molecular cancer therapeutics, 2015-12, Vol.14 (12), p.2805-2817

2015

Volltextzugriff (PDF)

A TORC2-Akt feedforward topology underlies HER3 resiliency in HER2-amplified cancers

Molecular cancer therapeutics, 2015-10, Vol.14 (12), p.2805-2817

2015

Volltextzugriff (PDF)

Disentangling multidimensional spatio-temporal data into their common and aberrant responses

PloS one, 2015-04, Vol.10 (4), p.e0121607-e0121607

2015

Volltextzugriff (PDF)

Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses: e0121607

PloS one, 2015-04, Vol.10 (4)

2015

Volltextzugriff (PDF)

Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3043-3043

2013

Volltextzugriff (PDF)

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

Biochemical journal, 2012-11, Vol.447 (3), p.417-425

2012

Volltextzugriff (PDF)

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

Seminars in cell & developmental biology, 2010-12, Vol.21 (9), p.944-950

2010

Volltextzugriff (PDF)

Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F

Cancer research (Chicago, Ill.), 2010-05, Vol.70 (9), p.3823-3832

2010

Volltextzugriff (PDF)

Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.1653-1653

2010

Volltextzugriff (PDF)

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

Science translational medicine, 2010-01, Vol.2 (16), p.16ra7

2010

Volltextzugriff (PDF)

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells

Microvascular research, 2008-05, Vol.76 (1), p.15-22

2008

Volltextzugriff (PDF)

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (4), p.2173-2180

2006

Volltextzugriff (PDF)

Neuregulin-regulated gene expression in mammary carcinoma cells

Experimental cell research, 2005-09, Vol.309 (1), p.12-23

2005

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Humans
(15)
Life Sciences & Biomedicine
(15)
Cell Line, Tumor
(9)
Oncology
(8)
Female
(7)
Breast Neoplasms - Genetics
(5)
Cell Biology
(5)
Animals
(4)
Biological And Medical Sciences
(4)
Breast Cancer
(4)
Mice
(4)
Proto-Oncogene Proteins C-Akt - Metabolism
(4)
Quinazolines - Pharmacology
(4)
Receptor, Erbb-2 - Metabolism
(4)
Receptor, Erbb-3 - Genetics
(4)
Receptor, Erbb-3 - Metabolism
(4)
Signal Transduction
(4)
Signal Transduction - Drug Effects
(4)
Adult
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Epidemiological Proileof Children with Malnutrition at Child Malnutrition Treatment Center (CMTC)in Saurashtra Region

Epidemiological Profile of Children with Malnutrition at Child Malnutrition Treatment Center (CMTC) in Saurashtra Region

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Intensive Care in India in 2018-2019: The Second Indian Intensive Care Case Mix and Practice Patterns Study

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study

Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injuries - United States, October 2019

Abstract 874: Pharmacologically induced RAS-GTP levels and CRAF-BRAF hetero-dimerization drive sensitization to Type II pan-RAF inhibitors in KRAS mutant cancer

Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1

Traumatic Lingual Hematoma Resulting in Bilateral Temporal Mandibular Joint Dislocations

Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin

Effective treatment of HER2-amplified breast cancer by targeting HER3 and [beta]1 integrin

Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib

A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers

A TORC2-Akt feedforward topology underlies HER3 resiliency in HER2-amplified cancers

Disentangling multidimensional spatio-temporal data into their common and aberrant responses

Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses: e0121607

Abstract 3043: Akt-mTorc2 signaling underlies cellular addiction to HER3 signaling in HER2-amplified cancers

HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

Id2 Promotes Tumor Cell Migration and Invasion through Transcriptional Repression of Semaphorin 3F

Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells

Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors

Neuregulin-regulated gene expression in mammary carcinoma cells

Suchergebnisse filtern